Lymphatica Medtech raises Series A round to start the clinical development and validation

Lymphatica Medtech, a vascular medical device development start-up, closes a seven-digit financing round to advance clinical validation aiming at revolutionizing the treatment of chronic lymphedema. The investment round was led by High-Tech Gründerfonds (HTGF), EIT health (European Institute of Innovation and Technology), business angels, and existing investor LIVEventures.

Lymphatica  Medtech is a Swiss medical device company founded in July 2017. It is a spin-off of the Swiss Federal Institute of Technology, Lausanne (EPFL – École Polytechnique Fédérale de Lausanne) and of the Lausanne University Hospital (CHUV - Centre Hospitalier Universitaire Vaudois). The company's vision is to become the leader in the development and marketing of innovative medical devices for the treatment of lymphatic diseases which will improve the quality of millions of people around the world.

Lymphatica Medtech will use the investment proceeds to start the clinical development and validation of LymphoDRAIN, its implantable device for the treatment of chronic lymphedema, which is one of the most common side effects of successful cancer treatment. Thanks to the Start-up Rescue Instrument from the EIT Health, Lymphatica will also improve the device connectivity through mobile apps.The investment round, led by High Tech Gründerfonds, was joined by business angels, the EIT Health (European Institute of Innovation and Technology), and existing investors, such as LIVEventures.

Lymphatica Medtech participated in Venture Kick in 2017 and Venture Leaders China in 2019. Marco Pisano, CEO and Co-Founder of Lymphatica Medtech says: "Quite simply, without Venture Kick in 2017, we would not be here today: it provided the crucial funding and connection to build the foundation of our business. Venture Leaders China was a very useful tool for expending our business strategy in respect to the internationalization plan, allowing to collect key information and contacts on the very relevant Chinese market. Even more, Venture Leaders significantly increased Lymphatica credibility with local investors."